Christos Gravvanis1, Labrini Papanastasiou2, Spiridoula Glycofridi2, Nikos Voulgaris3, Ernestini Tyfoxylou4, Kounadi Theodora2, George Piaditis5, Αthina Markou2. 1. Unit of Endocrinology and Diabetes Centre, General Hospital of Athens "G Gennimatas", 154 Mesogeion Avenue, 11527, Athens, Greece. christos_gravanis@hotmail.com. 2. Unit of Endocrinology and Diabetes Centre, General Hospital of Athens "G Gennimatas", 154 Mesogeion Avenue, 11527, Athens, Greece. 3. Department of Endocrinology, Athens Naval & Veterans Hospital, Athens, Greece. 4. Department of Endocrinology, 401 General Army Hospital Athens, Athens, Greece. 5. Department of Endocrinology, Henry Dunant Hospital Center, Athens, Greece.
Abstract
INTRODUCTION: Increased prevalence of hyperparathyroidism (HP) has been observed in primary aldosteronism (PA) patients. However, HP prevalence in milder forms of PA has not to date been evaluated. OBJECTIVES: The objectives of this study were to assess the prevalence of primary and secondary HP in overt and milder misdiagnosed cases of PA and to investigate the effect of treatment on parathormone (PTH) secretion. PATIENTS AND METHODS: Seventy PA patients with normal renal function were included prospectively. Specifically, patients with biochemically overt PA (increased basal aldosterone/renin ratio (ARR) and a positive diagnostic suppression test (DCVT)) and patients with mild PA (normal basal ARR and a positive DCVT) were analyzed. Mean blood pressure and mineral metabolism were evaluated at diagnosis and after treatment. RESULTS: Primary and secondary HP were found in 4.3% (3/70) and 51.4% (36/70) of patients, respectively, and biochemically overt and mild PA in 47.1% (33/70) and 52.9% (37/70) of patients, respectively. Sixty-three PA patients were followed up after treatment without receiving calcium or vitamin D. There was a decrease of mean blood pressure (p < 0.001), PTH (p < 0.001), and 24-h urinary calcium (p < 0.001), and an increase of serum potassium (p < 0.001) and calcium (p = 0.018) levels in secondary HP patients. There was no significant difference between biochemically overt and mild PA patients as concerned serum PTH, calcium, and 25-hydroxyvitamin-D levels either before or after treatment. Aldosterone levels before treatment were positively correlated with serum PTH levels. CONCLUSIONS: HP prevalence was high in both overt and mild PA patients, whereas the effect of treatment on serum and urinary calcium and PTH levels was similar in both groups.
INTRODUCTION: Increased prevalence of hyperparathyroidism (HP) has been observed in primary aldosteronism (PA) patients. However, HP prevalence in milder forms of PA has not to date been evaluated. OBJECTIVES: The objectives of this study were to assess the prevalence of primary and secondary HP in overt and milder misdiagnosed cases of PA and to investigate the effect of treatment on parathormone (PTH) secretion. PATIENTS AND METHODS: Seventy PA patients with normal renal function were included prospectively. Specifically, patients with biochemically overt PA (increased basal aldosterone/renin ratio (ARR) and a positive diagnostic suppression test (DCVT)) and patients with mild PA (normal basal ARR and a positive DCVT) were analyzed. Mean blood pressure and mineral metabolism were evaluated at diagnosis and after treatment. RESULTS: Primary and secondary HP were found in 4.3% (3/70) and 51.4% (36/70) of patients, respectively, and biochemically overt and mild PA in 47.1% (33/70) and 52.9% (37/70) of patients, respectively. Sixty-three PA patients were followed up after treatment without receiving calcium or vitamin D. There was a decrease of mean blood pressure (p < 0.001), PTH (p < 0.001), and 24-h urinary calcium (p < 0.001), and an increase of serum potassium (p < 0.001) and calcium (p = 0.018) levels in secondary HP patients. There was no significant difference between biochemically overt and mild PA patients as concerned serum PTH, calcium, and 25-hydroxyvitamin-D levels either before or after treatment. Aldosterone levels before treatment were positively correlated with serum PTH levels. CONCLUSIONS: HP prevalence was high in both overt and mild PA patients, whereas the effect of treatment on serum and urinary calcium and PTH levels was similar in both groups.
Authors: Ramachandran S Vasan; Jane C Evans; Martin G Larson; Peter W F Wilson; James B Meigs; Nader Rifai; Emelia J Benjamin; Daniel Levy Journal: N Engl J Med Date: 2004-07-01 Impact factor: 91.245
Authors: Andreas Tomaschitz; Eberhard Ritz; Burkert Pieske; Astrid Fahrleitner-Pammer; Katharina Kienreich; Jörg H Horina; Christiane Drechsler; Winfried März; Michael Ofner; Thomas R Pieber; Stefan Pilz Journal: Cardiovasc Res Date: 2012-02-13 Impact factor: 10.787
Authors: Vaios Tsiavos; Athina Markou; Labrini Papanastasiou; Theodora Kounadi; Ioannis I Androulakis; Nick Voulgaris; Aglaia Zachaki; Eva Kassi; Gregory Kaltsas; George P Chrousos; George P Piaditis Journal: Eur J Endocrinol Date: 2016-04-12 Impact factor: 6.664
Authors: Jenifer M Brown; Cassianne Robinson-Cohen; Miguel Angel Luque-Fernandez; Matthew A Allison; Rene Baudrand; Joachim H Ix; Bryan Kestenbaum; Ian H de Boer; Anand Vaidya Journal: Ann Intern Med Date: 2017-10-10 Impact factor: 25.391
Authors: Jenifer M Brown; Mohammed Siddiqui; David A Calhoun; Robert M Carey; Paul N Hopkins; Gordon H Williams; Anand Vaidya Journal: Ann Intern Med Date: 2020-05-26 Impact factor: 25.391